Evotec logo
Evotec
EVO | NASDAQ
Chart Builder DCF Calculator
$1.56
-$0.02 (-1.27%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Evotec Company Profile

Company profile explained

Company Profile

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

Key Executives

Name Position
Christian Wojczewski CEO & Chairperson of the Management Board
Aurelie Dalbiez Chief People Officer & Member of Management Board
Claire Hinshelwood Chief Financial Officer & Member of Management Board
Ingrid Mller Chief Operating Officer & Member of Management Board
Christian Dargel EVice President Global Head of Legal & Compliance
Christiane Honisch SVP Head of Diagnostics
Cord Dohrmann Chief Scientific Officer & Member of Management Board
David Hallet Executive Vice President
Ian Hunneyball Senior Vice President of Programme Management & Clinical Operations
Sarah Fakih Executive VP, Head of Global Communications & Investor Relations
Uwe Andag EVP Head of Metabolic Diseases

Latest SEC Filings

Date Type Title
Oct 15, 2026 6-K Filing
Oct 14, 2026 SC 13D/A [Amend] Filing
Oct 14, 2026 6-K Filing
Sep 29, 2026 6-K Filing
Sep 09, 2026 6-K Filing
Aug 13, 2026 6-K Filing
Jul 14, 2026 6-K Filing
Jun 30, 2026 6-K Filing
Jun 17, 2026 6-K Filing
May 06, 2026 6-K Filing
View All SEC Filings ➞
Evotec
Evotec logo
Country Germany
IPO Date Feb 5, 2004
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 4,553
CEO Christian Wojczewski

Contact Details

Essener Bogen 7 Hamburg, HA 22419 Germany

Stock Details

Ticker Symbol EVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001412558
CUSIP Number 30050E105
ISIN Number US30050E1055
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.